Corporate wealth or public health? WTO/TRIPS flexibilities and access to HIV/AIDS antiretroviral drugs by developing countries

Author： Love Roy

Publisher： Routledge Ltd

ISSN： 1364-9213

Source： Development in Practice, Vol.17, Iss.2, 2007-04, pp. : 208-219

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Health and wealth: Short panel Granger causality tests for developing countries

By Chen Weichun Clarke Judith A. Roy Nilanjana

Journal of International Trade & Economic Development, Vol. 23, Iss. 6, 2014-09 ,pp. : 755-784

Routledge Ltd

Access to resources Recommend Favorite

Social determinants of HIV/AIDS: implications for policies in emerging markets countries

By Mignone Javier

International Journal of Business and Emerging Markets, Vol. 5, Iss. 1, 2013-12 ,pp. : 83-97

Inderscience Publishers

Access to resources Recommend Favorite

Developing countries in the WTO: support or resist the 'millennium' round?

By Neumayer Eric

Development in Practice, Vol. 9, Iss. 5, 1999-11 ,pp. : 592-595

Routledge Ltd

Access to resources Recommend Favorite

“AIDS is Not a Business”: A Study in Global Corporate Responsibility – Securing Access to Low-cost HIV Medications

By Flanagan William

Journal of Business Ethics, Vol. 73, Iss. 1, 2007-06 ,pp. : 65-75

Springer Publishing Company

Access to resources Recommend Favorite

Corporate Governance Reforms in Developing Countries

By Reed D.

Journal of Business Ethics, Vol. 37, Iss. 3, 2002-05 ,pp. : 223-247

Springer Publishing Company

Access to resources Recommend Favorite